GL1X · GenesisL1 explorer

Research workbench

Crystal structure of a CHROMATE/URANIUM reductase from gluconacetobacter hansenii

Analyse Crystal structure of a CHROMATE/URANIUM reductase from gluconacetobacter… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3S2Y
Type
protein
Length
729 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Chromate reductase
UniProt
D5QFC5
Ligands
FMN, CL
Pockets
9 · best druggability 0.54

Structure

x-ray diffraction · 3 distinct chains · 43% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AChromate reductaseprotein18443% helix, 18% strandD5QFC5
B, DChromate reductaseprotein18243% helix, 19% strandD5QFC5
CChromate reductaseprotein18143% helix, 19% strandD5QFC5

Ligands and binding sites

  • FMN · Flavin mononucleotide · ligand · 4 copies · chains A, B, C, D
  • CL · Chloride ion · ion · 3 copies · chains B, C
  • PG4 · Tetraethylene glycol · additive · chains B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

9 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11900.540.7926FMN
21750.510.7826FMN
31910.490.7634empty
41200.400.7630empty
51110.370.7416empty

Interfaces

3 interfaces between chains.

  • B–C · 1456 Ų buried · 24 hydrogen bonds · protein-protein
  • A–B · 333 Ų buried · 0 hydrogen bonds · protein-protein
  • C–D · 320 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 3S2Y · Crystal structure of a chromate/uranium reductase from Gluconacetobacter hansenii · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.